Organogenesis Holdings ORGO 深 沪
等待开盘 12-18 09:30:00 美东时间
5.27
+0.100
+1.93%
华盛通- 最 高5.39
- 今 开5.05
- 成交量 210.24万股
- 最 低 5.0301
- 昨 收 5.17
- 总市值 6.69亿
- 52周最高 7.0771
- 市盈率 静 810.77
- 换手率 1.66%
- 52周最低 2.6101
- 委 比 -11.55%
- 总股本 1.27亿
- 历史最高 310.90
- 量 比 0.97
- 振 幅 6.96%
- 历史最低 1.795
- 每 手 1
- 风险率 0.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for December 16th
RILY: 50% | B. Riley Financial shares are trading higher after the company reported better-than-expected Q2 financial results. ORGO: 24% | Organogenesis Holdings shares are trading higher after the company
12-16 20:29
Biggest stock movers Tuesday: RILY, ORGO, KYTX, RC, LWLG and more
U.S. stock futures retreated Tuesday as investors adopted a cautious stance ahead of November’s employment data, a key indicator for the labor market’s health. Here are some of Tuesday's biggest stock...
12-16 18:17
Organogenesis Holdings Completes Type-B Meeting With FDA Resulting In Confirmation To Initiate Rolling BLA For ReNu Planned Before December End
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative
12-16 05:28
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
BTIG Maintains Buy on Organogenesis Holdings, Raises Price Target to $9
BTIG analyst Ryan Zimmerman maintains Organogenesis Holdings (NASDAQ:ORGO) with a Buy and raises the price target from $7 to $9.
11-20 20:51
Organogenesis Holdings Reports Record Revenue, Raises Guidance
Organogenesis Holdings ( ($ORGO) ) has released its Q3 earnings. Here is a brea...
11-07 13:54
CORRECTION: Organogenesis Hldgs Q3 Adj. EPS $0.18 Beats $0.06 Estimate, Sales $150.864M Beat $134.100M Estimate
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.06 by 221.82 percent. This is a 77 percent increase over earnings of $0.10 per share from
11-07 07:18
Organogenesis Holdings Raises FY2025 Net product revenue Guidance from $480.000M-$510.000M to $500.000M-$525.000M.
Organogenesis Holdings (NASDAQ:ORGO) raises FY2025 Net product revenue outlook from $480.000 million-$510.000 million to $500.000 million-$525.000 million.
11-07 07:12
Organogenesis Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.
Organogenesis Holdings shares are trading higher after the company reported bet...
11-07 06:00
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
